GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

One of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new treatment option for the country’s 30,000 or so people with HIV. Dovato (dolutegravir ...